Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7718634 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(3 months from now) | |
US7192938 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(3 months from now) | |
US7718634
(Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(9 months from now) | |
US7192938
(Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(9 months from now) |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 27 March, 1998
Treatment: Treatment of osteoporosis in postmenopausal women; Prevention and treatment of osteoporosis
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8246989 | APIL | Dosage forms of bisphosphonates |
Jan, 2026
(2 years from now) | |
US7645459 | APIL | Dosage forms of bisphosphonates |
Jan, 2028
(4 years from now) | |
US7645460 | APIL | Dosage forms of risedronate |
Jan, 2028
(4 years from now) |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 08 October, 2010
Treatment: Treatment of osteoporosis in postmenopausal women
Dosage: TABLET, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7572779 | APIL | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Oct, 2025
(2 years from now) |
Drugs and Companies using ESTRADIOL ACETATE ingredient
Market Authorisation Date: 20 August, 2004
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(6 years from now) |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 21 October, 2010
Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(6 years from now) |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 24 July, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET, CHEWABLE, TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic